2800 Patton Road
United States - Map
EnteroMedics Inc., a development stage medical device company, focuses on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. Its proprietary neuroblocking technology is designed to intermittently block the vagus nerve using electrical impulses. It is developing Maestro System, which is used to limit the expansion of the stomach, control hunger sensations between meals, reduce the frequency and intensity of stomach contractions, and produce a feeling of early and prolonged fullness. The company is evaluating the Maestro System in human clinical trials in the United States, Australia, Mexico, Norway, and Switzerland. It has collaboration with Mayo Clinic for research and development of its products. The company was formerly known as Beta Medical, Inc. and changed its name to EnteroMedics Inc. in 2003. EnteroMedics Inc. was founded in 2002 and is headquartered in St. Paul, Minnesota.
|EnteroMedics Inc.’s ISS Governance QuickScore as of May 1, 2013 is 10. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 5; Compensation: 10.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Dr. Mark B. Knudson Ph.D.,
Founder, Chairman, Chief Exec. Officer and Pres
|Dr. Katherine S. Tweden Ph.D.,
Co-Founder and VP of Clinical & Regulatory
|Mr. Gregory S. Lea ,
Chief Operating Officer, Chief Financial Officer, Principal Accounting Officer, Sr. VP and Sec.
|Mr. Adrianus Donders ,
Sr. VP of Research and Advanced Devel.
|Mr. Nicholas L. Teti Jr.,
Director, Special Advisor To Chief Exec. Officer and Member of Nominating & Governance Committee
|Amounts are as of Dec 30, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|